Takeda Pharmaceutical Company Limited (TAK)

Trade TAK now with
5/11/2022 2:21:15 AM Takeda Reports FY Revenue Growth Of 11.6%
4/18/2022 8:04:21 AM Takeda Announces Availability Of TAKHZYRO Injection Single-dose Prefilled Syringe In The U.S.
4/13/2022 2:17:34 AM Takeda Announces Completion Of Acquisition Of Own Shares
4/12/2022 7:04:35 AM Takeda Says Phase 3 SHP643-301 Study Evaluating Safety Profile And Pharmacokinetics Of TAKHZYRO Meets Objectives
2/28/2022 7:06:35 AM Takeda : Interim Phase 4 Data Support TAKHZYRO As Effective Treatment To Reduce Attacks In Hereditary Angioedema
2/18/2022 6:55:26 AM Takeda : Alofisel Shows Clinical Remission Rate At Six-Months In INSPIRE Study Interim Analysis On Crohn's Disease
2/3/2022 1:20:50 AM Takeda 9-month Reported EPS 154 Yen; Core EPS 333 Yen
1/31/2022 9:05:34 AM Takeda:FDA Oks Prophylactic Treatment With VONVENDI For Adult Patients Living With Severe Type 3 Von Willebrand Disease
12/2/2021 9:54:52 AM Takeda's LIVTENCITY Available For Individuals Ages 12 Yrs And Older With Post-Transplant CMV Infection/Disease In US
11/17/2021 8:17:13 AM Canadian Blood Services Awards Takeda Canada Three-Year Tender For Hemophilia Treatment ADYNOVATE
11/4/2021 9:24:32 AM Takeda Recommends Common-sense Policy Reforms